Menopause Management
On this page
Direct answer
Twelve consecutive months of amenorrhoea without another cause defines menopause — a clinical diagnosis needing no bloods when the woman is over 45 — with a mean age near 51 in Western data and commonly a few years earlier in Indian series (mid-to-late forties; figures vary by study). Management follows symptom burden and risk profile: menopausal hormone therapy (MHT) — oestrogen plus progestogen if the uterus is intact, oestrogen alone after hysterectomy — is the most effective treatment for vasomotor symptoms and genitourinary syndrome, most favourably initiated before 60 or within 10 years of the final period. Contraindications include undiagnosed bleeding, oestrogen-sensitive cancer, active venous thromboembolism and active liver disease. Non-hormonal options (selective serotonin reuptake inhibitors such as low-dose paroxetine, venlafaxine, gabapentin, clonidine, cognitive behavioural therapy) and topical vaginal oestrogen fill the gaps when hormones are refused or contraindicated.
What you must remember
- Diagnosis clinical at 45+: no FSH needed; under 45, FSH elevation on two occasions supports premature ovarian insufficiency, a separate management problem.
- MHT rule: oestrogen plus progestogen with a uterus (endometrial protection); oestrogen alone post-hysterectomy — using unopposed oestrogen in a woman with a uterus risks endometrial cancer.
- Transdermal 17β-oestradiol is preferred with migraine, or where venous thromboembolism risk is a concern, as it avoids the first-pass hepatic effect of oral therapy.
- Timing: start before 60 or within 10 years of menopause for the most favourable benefit-risk balance ("window of opportunity" concept); later initiation carries higher cardiovascular and thrombotic risk.
- WHI teaching points: combined therapy showed increased breast cancer and thrombotic events; oestrogen-alone therapy did not show a significant breast-cancer increase over the trial period.
- Genitourinary syndrome: low-dose vaginal oestrogen, moisturisers and lubricants are effective and systemically minimal — usable in many women in whom systemic MHT is contraindicated (per specialist input in hormone-sensitive cancer).
- Bone: calcium ~1000–1200 mg dietary plus 600–800 IU vitamin D, weight-bearing exercise, and formal fracture-risk assessment; MHT is bone-protective but not the preferred long-term osteoporosis drug in most guidelines.
- Bleeding after MHT establishment, or any postmenopausal bleeding, is investigated — endometrial assessment first.
How to work through a symptomatic patient
A 49-year-old perimenopausal teacher reports 8–12 hot flushes daily, night sweats fragmenting sleep, and irritability; her mother had breast cancer treated at 70, she has a BMI of 31, and her uterus is intact. Structured counselling: her symptoms are classic; MHT would relieve them better than anything else, but her risks (thrombotic with obesity, family breast cancer history) shape the choices. Plan: transdermal oestradiol 50 µg with micronised progestogen (or a progestogen-releasing intrauterine system for the endometrium), reviewed at 3 months, then annually — duration individualised to the lowest effective dose rather than an arbitrary stop date. Weight management proceeds in parallel because it independently improves flushes and thrombotic risk.
The third scenario is the 53-year-old, five years post-menopause, with dyspareunia and urinary urgency but no flushes: she does not need systemic MHT at all. Vaginal low-dose oestrogen with moisturisers and lubricants treats genitourinary syndrome directly, and pelvic floor physiotherapy addresses the urinary component — the exam point being that topical therapy is a different risk category from systemic therapy.
Where students slip
First error: prescribing unopposed oestrogen to a woman with a uterus — the endometrial cancer risk is the single most-tested fact in this territory. Second, quoting WHI as "hormones cause breast cancer" without the oestrogen-alone nuance or the timing stratification. Third, ordering FSH to "diagnose menopause" in a 52-year-old with classic symptoms — wasted testing in the over-45s, while under-40s with amenorrhoea (premature ovarian insufficiency) genuinely need the workup and replacement until at least natural menopause age. Fourth, forgetting that postmenopausal bleeding is never "just the hormones" — it is endometrial cancer until investigated, whatever the MHT status.
Frequently asked questions
When can menopause be diagnosed clinically without blood tests?
In women 45 or over with typical vasomotor symptoms and 12 months of amenorrhoea, no confirmatory testing is needed; FSH measurement is reserved for atypical presentations, contraception needs, or suspected premature ovarian insufficiency under 40–45.
Why is a progestogen added to oestrogen therapy?
To protect the endometrium: unopposed oestrogen drives endometrial proliferation and carcinoma, so any woman with an intact uterus receiving systemic oestrogen also receives a progestogen (or a levonorgestrel intrauterine system).
What are the non-hormonal treatments for hot flushes?
Low-dose paroxetine (the best-evidenced SSRI for flushes), venlafaxine, gabapentin, clonidine, and structured cognitive behavioural therapy; weight loss, layered clothing and trigger avoidance support them.
Is vaginal oestrogen safe in women who cannot take systemic MHT?
Low-dose vaginal oestrogen has minimal systemic absorption and is standard care for genitourinary syndrome of menopause, including many women with contraindications to systemic therapy — with specialist input in hormone-sensitive cancer survivors.
How is bone health managed after menopause?
Adequate calcium and vitamin D, weight-bearing and resistance exercise, smoking and alcohol moderation, fracture-risk assessment, and specific anti-osteoporosis therapy when risk is elevated — MHT contributes bone benefit but is not the usual long-term choice for osteoporosis treatment.